Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.

Clinical pharmacology and therapeutics - 1 May 1998

Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J

Abstract excerpt

OBJECTIVE: To determine whether cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of tolterodine by investigating potential differences in pharmacokinetics and pharmacodynamic (heart rate, accommodation, and salivation) of tolterodine and its 5-hydroxymethyl metabolite between poor metabolizers and extensive metabolizers of debrisoquin (INN, debrisoquine). METHODS: Sixteen male subjects (eight extensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Debrisoquin

Share to Half-Life

Share to Heart Rate

Share to Metabolic Clearance Rate

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 9630826
DOI: 10.1016/S0009-9236(98)90104-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.PMID 9630826Read ↗

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.Semantic proximity Read ↗

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.Semantic proximity Read ↗

Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.Semantic proximity Read ↗

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.Semantic proximity Read ↗

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.Semantic proximity Read ↗

The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.Semantic proximity Read ↗

Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.Semantic proximity Read ↗

Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.